Subject who has concurrent skin disease (eg, acne) of such severity in the study area that it could interfere with study evaluation; Subject who has active or recent skin infections (within 7 days of randomization); Subject who has received phototherapy (eg, UVA, UVB) known or suspected to have an effect on AD within 6 weeks prior to randomization; Subject who has received corticosteroids by other than topical, inhaled or intranasal delivery within 4 weeks prior to randomization; Subject who has been treated with topical calcineurin inhibitors within 14 days prior to randomization; Subject who uses any medications that interfere with blood coagulation (eg NSAIDs) or wound healing within 7 days or 5 half-lives (whichever is longer) prior to enrolling into the study and for the duration of the study.